Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “Proper Management” Essential in Company Funding of Academic Research: MHLW Official
April 15, 2015
- PMDA Invites People with Broad Perspective from the Medical Community to Join PMDA: Chief Executive
April 15, 2015
- MHLW Official Introduces Patient ADR Reporting System
April 15, 2015
- Cost-Effectiveness Case Study to Be Reported to Chuikyo in May: Official
April 14, 2015
- If Cost-Effective Assessment Is Used to Set Drug Prices, Focus Will Be on Impact on Pricing Rules: Ex-Chuikyo Member
April 14, 2015
- Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
- JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
- PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
- Consumer Affairs Agency Warns Public of Adverse Reaction Risks of OTC Drugs
April 10, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- Chuikyo to Focus Sights on Unused Medication, Long-Term Prescriptions in Discussions
April 9, 2015
- Orphan Designation System Should Be Adjusted for Factors Including Company Scale: Report
April 8, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- MEXT Secures FY2015 Budgets for Generic Promotion Subsidy Project
April 7, 2015
- Overlapping of All-Case Surveys and EPPV Inefficient: Mr Uda of FPMAJ
April 7, 2015
- PMDA Reviewing Plavix for Risk of Acute Generalized Exanthematous Pustulosis
April 6, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 23 - April 5
April 6, 2015
- Govt, Pharma Leaders to Hold Policy Dialogue on April 13
April 6, 2015
- Abe Pins Hopes of Innovation on AMED
April 6, 2015
- MHLW to Accept Applications for “Sakigake” Designation from May 8
April 6, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…